文献速递血液透析通路

美国血液透析血管通路的利用、通畅率及相关并发症

Utilization, patency, and complications associated with vascular access for hemodialysis in the United States.
PubMed 文献 · J Vasc Surg · 2018-01-01

该回顾性研究利用美国肾脏数据系统-医疗保险匹配数据库,分析2007至2011年起始血液透析患者的血管通路利用与结局。结果显示,临时导管过渡与死亡率升高、感染增加和通畅率降低相关;自体动静脉瘘较人工血管移植物通畅率更优、感染和死亡风险更低,但无导管透析时间更长。

要点

  • 临时导管过渡与死亡率增加51%、主要通畅率降低69%、严重感染增加130%相关。
  • 自体动静脉瘘较人工血管移植物主要通畅率和主要辅助通畅率更高,严重感染和死亡风险更低。
  • 持续使用导管的患者死亡率是起始即用自体动静脉瘘患者的2.25倍。

核心结论

  • 临时导管使用与更高的死亡率、更高的感染率和更低的通畅率相关,削弱了以导管作为永久通路桥梁的普遍做法。
  • 在一般人群中,自体动静脉瘘较人工血管移植物无导管透析时间更长,但通畅率更好、感染风险更低、死亡率更低。

研究设计与样本

  • 回顾性研究,纳入美国2007至2011年5年期间所有起始血液透析的患者,使用美国肾脏数据系统-医疗保险匹配全国数据库。
  • 比较预先放置的自体动静脉瘘、预先放置的人工血管移植物、临时导管后自体动静脉瘘、临时导管后人工血管移植物以及持续使用导管等组的结局。
  • 结局包括主要通畅率、主要辅助通畅率、次要通畅率、成熟、无导管透析、严重通路感染和死亡率。

主要发现

  • 起始血液透析时使用自体动静脉瘘者73884例(16%),使用人工血管移植物者16533例(3%),先使用临时导管再使用自体动静脉瘘者106797例(22%),先使用临时导管再使用人工血管移植物者32890例(7%),持续使用导管者246822例(52%)。
  • 预先放置的自体动静脉瘘 vs 人工血管移植物:成熟率79% vs 84%,中位成熟时间47天 vs 29天。
  • 自体动静脉瘘 vs 人工血管移植物:主要通畅率aHR 1.26(95%CI 1.25-1.28,P<.001),主要辅助通畅率aHR 1.36(95%CI 1.35-1.38,P<.001),均显著更高。
  • 自体动静脉瘘 vs 人工血管移植物:2个月后次要通畅率更高(aHR 1.36,95%CI 1.32-1.40,P<.001);人工血管移植物严重感染aHR 9.6(95%CI 8.86-10.36,P<.001),死亡aHR 1.29(95%CI 1.27-1.31,P<.001),均更高。
  • 与起始即用自体动静脉瘘或人工血管移植物相比,临时导管过渡与死亡率增加51%(aHR 1.51,95%CI 1.48-1.53,P<.001)、主要通畅率降低69%(aHR 0.31,95%CI 0.31-0.32,P<.001)、严重感染增加130%(aHR 2.3,95%CI 2.2-2.5,P<.001)相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study examines the utilization and outcomes of vascular access for long-term hemodialysis in the United States and describes the impact of temporizing catheter use on outcomes. We aimed to evaluate the prevalence, patency, and associated patient survival for pre-emptively placed autogenous fistulas and prosthetic grafts; for autogenous fistulas and prosthetic grafts placed after a temporizing catheter; and for hemodialysis catheters that remained in use. METHODS: We performed a retrospective study of all patients who initiated hemodialysis in the United States during a 5-year period (2007-2011). The United States Renal Data System-Medicare matched national database was used to compare outcomes after pre-emptive autogenous fistulas, preemptive prosthetic grafts, autogenous fistula after temporizing catheter, prosthetic graft after temporizing catheter, and persistent catheter use. Outcomes were primary patency, primary assisted patency, secondary patency, maturation, catheter-free dialysis, severe access infection, and mortality. RESULTS: There were 73,884 (16%) patients who initiated hemodialysis with autogenous fistula, 16,533 (3%) who initiated hemodialysis with prosthetic grafts, 106,797 (22%) who temporized with hemodialysis catheter prior to autogenous fistula use, 32,890 (7%) who temporized with catheter prior to prosthetic graft use, and 246,822 (52%) patients who remained on the catheter. Maturation rate and median time to maturation were 79% vs 84% and 47 days vs 29 days for pre-emptively placed autogenous fistulas vs prosthetic grafts. Primary patency (adjusted hazard ratio [aHR], 1.26; 95% confidence interval [CI], 1.25-1.28; P < .001) and primary assisted patency (aHR, 1.36; 95% CI, 1.35-1.38; P < .001) were significantly higher for autogenous fistula compared with prosthetic grafts. Secondary patency was higher for autogenous fistulas beyond 2 months (aHR, 1.36; 95% CI, 1.32-1.40; P < .001). Severe infection (aHR, 9.6; 95% CI, 8.86-10.36; P < .001) and mortality (aHR, 1.29; 95% CI, 1.27-1.31; P < .001) were higher for prosthetic grafts compared with autogenous fistulas. Temporizing with a catheter was associated with a 51% increase in mortality (aHR, 1.51; 95% CI, 1.48-1.53; P < .001), 69% decrease in primary patency (aHR, 0.31; 95% CI, 0.31-0.32; P < .001), and 130% increase in severe infection (aHR, 2.3; 95% CI, 2.2-2.5; P < .001) compared to initiation with autogenous fistulas or prosthetic grafts. Mortality was 2.2 times higher for patients who remained on catheters compared to those who initiated hemodialysis with autogenous fistulas (aHR, 2.25; 95% CI, 2.21-2.28; P < .001). CONCLUSIONS: Temporizing catheter use was associated with higher mortality, higher infection, and lower patency, thus undermining the highly prevalent approach of electively using catheters as a bridge to permanent access. Autogenous fistulas are associated with longer time to catheter-free dialysis but better patency, lower infection risk, and lower mortality compared with prosthetic grafts in the general population.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Arhuidese IJ, Orandi BJ, Nejim B, et al. Utilization, patency, and complications associated with vascular access for hemodialysis in the United States. J Vasc Surg. 2018. PMID: 30244924. doi:10.1016/j.jvs.2018.01.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。